145 related articles for article (PubMed ID: 31321405)
1. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era.
Kaplovitch E; Anand SS
Cardiovasc Res; 2019 Oct; 115(12):e121-e124. PubMed ID: 31321405
[No Abstract] [Full Text] [Related]
2. Rivaroxaban in peripheral artery disease: The new kid on the block?
Hussain MA; Verma S; Al-Omran M
J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
[No Abstract] [Full Text] [Related]
3. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Boden WE; Bhatt DL
Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
[No Abstract] [Full Text] [Related]
4. Antithrombotic therapy in peripheral artery disease.
Foley TR; Waldo SW; Armstrong EJ
Vasc Med; 2016 Apr; 21(2):156-69. PubMed ID: 26823456
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
[No Abstract] [Full Text] [Related]
6. The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial.
Fukaya E; Leeper NJ
Cardiovasc Res; 2020 Oct; 116(12):e156-e158. PubMed ID: 32980875
[No Abstract] [Full Text] [Related]
7. Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
García-Ropero Á; Vargas-Delgado AP; Santos-Gallego CG; Badimon JJ
J Cardiovasc Pharmacol; 2020 Apr; 75(4):269-275. PubMed ID: 31923049
[TBL] [Abstract][Full Text] [Related]
8. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Patrono C
Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
[No Abstract] [Full Text] [Related]
9. Patients with Peripheral Artery Disease in the COMPASS Trial.
Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
[No Abstract] [Full Text] [Related]
10. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
Filippatos G; Farmakis D
Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
[No Abstract] [Full Text] [Related]
11. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
12. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.
Patel SM; Morrow DA; Kidd SK; Goodrich EL; Scirica BM; Bonaca MP
Vasc Med; 2019 Apr; 24(2):159-161. PubMed ID: 30868939
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of DOACs in patients with peripheral arterial disease: A systematic review and meta-analysis.
Zhang YS; Chen JH; Mei T; Li S; Lu YM
Vascular; 2021 Dec; 29(6):846-855. PubMed ID: 33504278
[TBL] [Abstract][Full Text] [Related]
14. Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
Wand S; Baro D; Baecker C; Meybohm P; Schmitz-Rixen T; Zacharowski K; Mutlak H; Weber CF
Clin Lab; 2014; 60(10):1601-7. PubMed ID: 25651704
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
[TBL] [Abstract][Full Text] [Related]
16. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coppens M; Weitz JI; Eikelboom JWA
Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
[TBL] [Abstract][Full Text] [Related]
17. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
Mackman N; Spronk HMH; Stouffer GA; Ten Cate H
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):726-732. PubMed ID: 29449336
[No Abstract] [Full Text] [Related]
18. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Kruger PC; Eikelboom JW; Yusuf S
Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
[No Abstract] [Full Text] [Related]
20. Triple therapy: worth the risk?
Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
